The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy(Roswell Park Comprehensive Cancer Center), Agnieszka K. Witkiewicz(Southwestern Medical Center)
Cited by 45
Related Papers
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
|Nature Communications|2015|1.1k
Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
|BMC Cancer|2015|36
Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
|Nature Communications|2025|28
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative
|International Journal of Oncology|2017|15